Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Darci Phillips, Magdalena Matusiak, Belén Rivero Gutierrez, Salil S. Bhate, Graham L. Barlow, Sizun Jiang, Janos Demeter, Kimberly S. Smythe, Robert H. Pierce, Steven P. Fling, Nirasha Ramchurren, Martin A. Cheever, Yury Goltsev, Robert B. West, Michael S. Khodadoust, Youn H. Kim, Christian M. Schürch, Garry P. Nolan
doi: https://doi.org/10.1101/2020.12.06.20244913
Darci Phillips
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
2Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Matusiak
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belén Rivero Gutierrez
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salil S. Bhate
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
4Department of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham L. Barlow
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sizun Jiang
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janos Demeter
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly S. Smythe
5Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert H. Pierce
5Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven P. Fling
5Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nirasha Ramchurren
5Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin A. Cheever
5Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yury Goltsev
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert B. West
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael S. Khodadoust
6Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youn H. Kim
2Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
6Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian M. Schürch
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christian.m.schuerch@gmail.com gnolan@stanford.edu
Garry P. Nolan
1Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christian.m.schuerch@gmail.com gnolan@stanford.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Anti-PD-1 immunotherapies have transformed cancer treatment, yet the determinants of clinical response are largely unknown. We performed CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced cutaneous T cell lymphoma (CTCL) patients enrolled in a clinical trial of pembrolizumab therapy. Clinical response was not associated with the frequency of tumor-infiltrating T cell subsets, but rather with striking differences in the spatial organization and functional immune state of the tumor microenvironment (TME). After treatment, pembrolizumab responders had a localized enrichment of tumor and CD4+ T cells, which coincided with immune activation and cytotoxic PD-1+ CD4+ T cells. In contrast, non-responders had a localized enrichment of Tregs pre- and post-treatment, consistent with a persistently immunosuppressed TME and exhausted PD-1+ CD4+ T cells. Integrating these findings by computing the physical distances between PD-1+ CD4+ T cells, tumor cells, and Tregs revealed a spatial biomarker predictive of pembrolizumab response. Finally, the chemokine CXCL13 was upregulated in tumor cells in responders post-treatment, suggesting that chemoattraction of PD-1+ CD4+ T cells towards tumor cells facilitates a positive outcome. Together, these data show that T cell topography reflects the balance of effector and suppressive activity within the TME and predicts clinical response to PD-1 blockade in CTCL.

Competing Interest Statement

G.P.N. and Y.G. are co-founders and stockholders of Akoya Biosciences, Inc. and inventors on patent US9909167. D.P., C.M.S., and G.P.N. are inventors on pending patent US62971722, filed by Stanford University. C.M.S. is a scientific advisor to Enable Medicine, LLC. Y.H.K. received research funding from Merck & Co. The other authors declare no competing interests.

Funding Statement

This work was supported by the National Institutes of Health (NIH) 2U19AI057229-16, 5P01HL10879707, 5R01GM10983604, 5R33CA18365403, 5U01AI101984-07, 5UH2AR06767604, 5R01CA19665703, 5U54CA20997103, 5F99CA212231-02, 1F32CA233203-01, 5U01AI140498-02, 1U54HG010426-01, 5U19AI100627-07, 1R01HL120724-01A1, R33CA183692, R01HL128173-04, 5P01AI131374-02, 5UG3DK114937-02, 1U19AI135976-01, IDIQ17X149, 1U2CCA233238-01, 1U2CCA233195-01 (G.P.N.), F32CA233203 (D.P.), T32AR007422 (D.P.), T32AI007290 (G.L.B.); The National Cancer Institute: U01CA154967 and UM1CA154967 (M.A.C., S.P.F.); Cancer Center Support Grant P30 CA015704. The Department of Defense (W81XWH-14-1-0180 and W81XWH-12-1-0591) (G.P.N.); The Food and Drug Administration (HHSF223201610018C and DSTL/AGR/00980/01) (G.P.N.); Cancer Research UK (C27165/A29073) (G.P.N.); The Bill and Melinda Gates Foundation (OPP1113682) (G.P.N.); The Cancer Research Institute (G.P.N.); The Parker Institute for Cancer Immunotherapy (G.P.N.); The Kenneth Rainin Foundation (2018-575) (G.P.N.); Celgene, Inc. (133826 and 134073) (G.P.N.); the Rachford & Carlotta A. Harris Endowed Chair (G.P.N.); and The Beckman Center for Molecular and Genetic Medicine (D.P., C.M.S., Y.H.K, G.P.N.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The use of human tissues for this research was fully de-personalized and approved by the Stanford University IRB Administrative Panels on Human Subjects in Medical Research (HSR 46894).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data generated or analyzed in this study are included in this Medrxiv article or available upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 08, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Darci Phillips, Magdalena Matusiak, Belén Rivero Gutierrez, Salil S. Bhate, Graham L. Barlow, Sizun Jiang, Janos Demeter, Kimberly S. Smythe, Robert H. Pierce, Steven P. Fling, Nirasha Ramchurren, Martin A. Cheever, Yury Goltsev, Robert B. West, Michael S. Khodadoust, Youn H. Kim, Christian M. Schürch, Garry P. Nolan
medRxiv 2020.12.06.20244913; doi: https://doi.org/10.1101/2020.12.06.20244913
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Darci Phillips, Magdalena Matusiak, Belén Rivero Gutierrez, Salil S. Bhate, Graham L. Barlow, Sizun Jiang, Janos Demeter, Kimberly S. Smythe, Robert H. Pierce, Steven P. Fling, Nirasha Ramchurren, Martin A. Cheever, Yury Goltsev, Robert B. West, Michael S. Khodadoust, Youn H. Kim, Christian M. Schürch, Garry P. Nolan
medRxiv 2020.12.06.20244913; doi: https://doi.org/10.1101/2020.12.06.20244913

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (217)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1112)
  • Dentistry and Oral Medicine (197)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (508)
  • Epidemiology (9807)
  • Forensic Medicine (5)
  • Gastroenterology (482)
  • Genetic and Genomic Medicine (2335)
  • Geriatric Medicine (223)
  • Health Economics (464)
  • Health Informatics (1569)
  • Health Policy (738)
  • Health Systems and Quality Improvement (609)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11674)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2162)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (520)
  • Oncology (1187)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (700)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2196)
  • Public and Global Health (4694)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (459)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (227)
  • Sports Medicine (214)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)